Propensity score matching and persistence correction to reduce bias in comparative effectiveness: the effect of cinacalcet use on all-cause mortality.

24 Although there were numerically fewer primary composite endpoints (time to death or first non‐fatal cardiovascular event) in patients randomised to cinacalcet compared with those of placebo, this difference failed to reach statistical significance in unadjusted intention‐to‐treat analysis. 24 Pre‐specified secondary and sensitivity analyses such as covariate adjustment and lag‐censoring, however, revealed a nominally significant 12–15% risk reduction with cinacalcet. 24 All‐cause mortality was analysed as described previously for the primary composite endpoint.

also in 6,035 other papers

24 Pre‐specified secondary and sensitivity analyses such as covariate adjustment and lag‐censoring, however, revealed a nominally significant 12–15% risk reduction with cinacalcet. 24 All‐cause mortality was analysed as described previously for the primary composite endpoint.

also in 7,732 other papers